1. Introduction {#sec1-cancers-12-02111}
===============

Starting from a trend-break in 1955, the incidence of malignant melanoma (MM) has increased steadily in Caucasian populations, which points to changes in lifestyle and environment \[[@B1-cancers-12-02111],[@B2-cancers-12-02111],[@B3-cancers-12-02111],[@B4-cancers-12-02111]\]. To clarify the pathogenesis of MM, efforts have been focused on the identification of MM oncogenes, such as *NRAS, BRAF, PTEN, MITF, NEDD9, hTERT* and *KIT*, which have led to an improved understanding of MM etiology and opened new avenues for personalized treatment \[[@B5-cancers-12-02111],[@B6-cancers-12-02111],[@B7-cancers-12-02111],[@B8-cancers-12-02111],[@B9-cancers-12-02111],[@B10-cancers-12-02111]\]. However, not only genetic deviations promote MM initiation, proliferation and progression but also epigenetic mechanisms including aberrant DNA- methylations and changes in microRNA (miR) expression, extensively reviewed elsewhere \[[@B11-cancers-12-02111],[@B12-cancers-12-02111],[@B13-cancers-12-02111],[@B14-cancers-12-02111],[@B15-cancers-12-02111],[@B16-cancers-12-02111],[@B17-cancers-12-02111],[@B18-cancers-12-02111],[@B19-cancers-12-02111],[@B20-cancers-12-02111],[@B21-cancers-12-02111],[@B22-cancers-12-02111],[@B23-cancers-12-02111]\]. The present review focuses on miR-21, which is a key oncogenic miR overexpressed in MM, glioblastoma and other common cancers of Western societies \[[@B24-cancers-12-02111],[@B25-cancers-12-02111],[@B26-cancers-12-02111],[@B27-cancers-12-02111]\]. MiR-21 is also increased in serum and plasma of MM patients and is regarded as a potential biomarker of MM \[[@B28-cancers-12-02111],[@B29-cancers-12-02111],[@B30-cancers-12-02111]\]. This review highlights three major aspects: (1) The role of miR-21 signaling in MM pathogenesis and progression, (2) the impact of environmental factors enhancing miR-21 in MM and MM microenvironment with special attention to exosome-derived miR-21, and (3) potential therapeutic options that attenuate miR-21 signaling in MM. Translational evidence indicates that metabolic, environmental and lifestyle factors increase miR-21 expression including exosomal miR-21 trafficking involved in melanomagenesis and MM progression.

2. Methodological Approach {#sec2-cancers-12-02111}
==========================

The PubMed database was searched from July 2010 to July 2020 for microRNA-21-melanoma interactions including cutaneous and uveal melanoma, rodent melanoma models, and melanoma cell lines including human A375 and murine B16 melanoma cells. MiR-21 target gene interactions were controlled by TargetScanHuman and miRBase. Selected key words for literature search were: melanoma, cutaneous melanoma, uveal melanoma, malignant melanoma, microRNA-21, miRNA-21, miR-21, radiation, cosmic radiation, electromagnetic radiation, ultraviolet radiation, exosomes, melanoma exosomes, aging, lifestyle, diabetes mellitus, obesity, diabesity, metabolism, metabolic syndrome, melanoma microenvironment, immune regulation, Western diet, hyperglycemic diet, and high-fat diet.

3. Mechanism of Action of MiR-21 in Melanoma and Melanoma Cells {#sec3-cancers-12-02111}
===============================================================

3.1. MiR-21 in Melanoma Pathogenesis and Progression {#sec3dot1-cancers-12-02111}
----------------------------------------------------

MiR-21 targets key genes involved in melanomagenesis and MM progression. MiR-21 regulates genes that are involved in MM proliferation, G~1~/S transition and invasion \[[@B31-cancers-12-02111],[@B32-cancers-12-02111]\]. Its expression steadily raises with the progression of benign nevi to primary and metastatic MM, correlates with Breslow tumor thickness and advanced clinical stage \[[@B31-cancers-12-02111],[@B33-cancers-12-02111]\]. Compared with benign nevi, primary cutaneous MM had an 8.6-fold overexpression of miR-21, which was associated with mitotic activity \[[@B34-cancers-12-02111]\]. Positive sentinel lymph node biopsy (SLNB) was related to increased miR-21 expression in the primary lesion compared with lesions with a negative SLNB ([Table 1](#cancers-12-02111-t001){ref-type="table"}) \[[@B34-cancers-12-02111]\]. MiRNA-21 is also upregulated in uveal melanoma \[[@B35-cancers-12-02111]\]. Patients with high miR-21 expression show shorter five-year disease-free or overall survival than those with low miR-21 expression \[[@B33-cancers-12-02111]\]. In contrast, antisense-mediated miR-21 inhibition suppresses growth, increases apoptosis and enhances chemo- or radiosensitivity of human MM cells \[[@B33-cancers-12-02111]\]. Thus, miR-21 is a pivotal MM oncomiR that promotes melanomagenesis and MM progression.

3.2. MiR-21 Targets in Melanoma Cells {#sec3dot2-cancers-12-02111}
-------------------------------------

MiR-21 expression in MM is inversely associated with nuclear expression of phosphatase and tensin homolog (PTEN) \[[@B39-cancers-12-02111]\]. In human melanoma A375 cells, miR-21 promotes proliferation, migration, and suppresses apoptosis by inhibiting Sprouty 1 (SPRY1), programmed cell death 4 (PDCD4), PTEN and cyclin-dependent kinase inhibitor 2C (CDKN2C) \[[@B32-cancers-12-02111],[@B39-cancers-12-02111],[@B40-cancers-12-02111]\]. Increased cellular miR-21 levels distinguish MM from nevi and correlate with MM cellularity \[[@B36-cancers-12-02111]\]. Remarkably, BRAF or NRAS mutations in MM had no significant effect on miR-21 expression \[[@B39-cancers-12-02111]\]. MiR-21 directly targets Sprouty 1 (*SPRY1*), Sprouty 2 (*SPRY2*), B-cell translocation gene 2 (*BTG2*) and inactivates tumor necrosis factor-α-induced protein 8-like 2 (*TIPE2*), which are key post-transcriptional inhibitors of RAS and RAF, respectively \[[@B40-cancers-12-02111],[@B41-cancers-12-02111],[@B42-cancers-12-02111],[@B43-cancers-12-02111],[@B44-cancers-12-02111],[@B45-cancers-12-02111],[@B46-cancers-12-02111],[@B47-cancers-12-02111],[@B48-cancers-12-02111]\]. Via targeting various inhibitors of the RAS-MEK-ERK pathway, miR-21 may induce an autoregulatory mechanism promoting RAS transformation ([Figure 1](#cancers-12-02111-f001){ref-type="fig"}) \[[@B47-cancers-12-02111],[@B48-cancers-12-02111]\]. MiR-21-mediated suppression of the RAS inhibitor BTG2 enhances RAS-MEK-ERK-AP-1 signaling to maintain enhanced miR-21 expression ([Figure 1](#cancers-12-02111-f001){ref-type="fig"}) \[[@B47-cancers-12-02111],[@B48-cancers-12-02111]\].

3.3. Endogenous Upregulation of MiR-21 in Melanoma {#sec3dot3-cancers-12-02111}
--------------------------------------------------

*MiR-21* gene expression is primarily upregulated by the enhancer *signal transducer and activator of transcription 3* (STAT3) and the promoter *activator protein 1* (AP-1). At the post-transcriptional level, cellular miR-21 concentrations are also regulated by long non-coding RNAs (lncRNAs). [Table 2](#cancers-12-02111-t002){ref-type="table"} presents an overview of melanoma-related miR-21 target genes that are involved in the pathogenesis of MM.

### 3.3.1. Signal Transducer and Activator of Transcription 3 {#sec3dot3dot1-cancers-12-02111}

Activation of miR-21 expression via STAT3 represents an epigenetic switch linking inflammation to cancer \[[@B61-cancers-12-02111]\]. STAT3 is commonly activated during MM progression and promotes metastasis \[[@B62-cancers-12-02111],[@B63-cancers-12-02111]\]. Stress-induced phosphoprotein 1 (STIP1) is overexpressed in MM compared to benign nevi and normal skin, respectively \[[@B64-cancers-12-02111]\]. STIP1 stimulates the expression of Janus kinase 2 (JAK2), which activates STAT3 ([Figure 1](#cancers-12-02111-f001){ref-type="fig"}) \[[@B64-cancers-12-02111]\]. STAT3 plays an important role in self-renewal of MM stem-like cells \[[@B65-cancers-12-02111]\]. Accordingly, targeting STAT3 sensitizes human MM cells to the BRAF inhibitor vemurafenib \[[@B66-cancers-12-02111]\]. Intradermal delivery of STAT3 siRNA effectively suppresses MM \[[@B67-cancers-12-02111]\]. A significant association between STAT3 inhibition and the response to nilotinib has also been reported in KIT-mutated MM \[[@B68-cancers-12-02111]\]. STAT3 is an enhancer of miR-21 expression confirmed in B16 MM cells ([Figure 1](#cancers-12-02111-f001){ref-type="fig"}) \[[@B57-cancers-12-02111],[@B69-cancers-12-02111],[@B70-cancers-12-02111],[@B71-cancers-12-02111]\]. Of interest, growth hormone (GH), epidermal growth factor (EGF), leptin, interleukins 6 (IL-6) and IL-10 activate the JAK2-STAT3 pathway thereby promoting miR-21-driven melanomagenesis ([Figure 2](#cancers-12-02111-f002){ref-type="fig"}) \[[@B63-cancers-12-02111]\].

### 3.3.2. Hippo Pathway {#sec3dot3dot2-cancers-12-02111}

Yes-associated protein (YAP) and its homolog transcriptional coactivator with PDZ-binding motif (TAZ) are key effectors of the Hippo pathway that control cell growth, organ size and tumorigenesis \[[@B72-cancers-12-02111]\]. YAP expression is elevated in most benign nevi and primary cutaneous MMs and uveal MMs \[[@B73-cancers-12-02111],[@B74-cancers-12-02111],[@B75-cancers-12-02111]\]. Gains of copy numbers directly affect YAP and are in the range of 4--10%, and 62% of MMs had copy number alterations affecting Hippo pathway genes \[[@B76-cancers-12-02111]\]. Upon activation, YAP/TAZ-complexes translocate into the nucleus to promote proliferation. An early downstream effector of the Hippo pathway is FOS, a component of AP-1 \[[@B72-cancers-12-02111]\], which promotes miR-21 expression.

### 3.3.3. Long Non-Coding RNAs {#sec3dot3dot3-cancers-12-02111}

LncRNAs represent a group of transcripts with a length of \>200 nucleotides, which play a role in the onset and development of MM \[[@B77-cancers-12-02111]\]. The *X-inactive-specific transcript* (XIST) is one of the first lncRNAs discovered in mammals and plays an essential role in X chromosome inactivation. XIST is dysregulated and acts as an oncogene or as a tumor suppressor in different human malignancies \[[@B78-cancers-12-02111]\]. XIST operates as a miR sponge inhibiting miR-21 \[[@B79-cancers-12-02111]\]. A recent study showed that XIST is overexpressed in MM tissues and cell lines, whereas XIST knockdown inhibits proliferation and migration in MM cells and increases the oxaliplatin sensitivity of resistant MM cells \[[@B80-cancers-12-02111]\]. XIST expression is also upregulated in glioma and glioblastoma stem cells \[[@B81-cancers-12-02111],[@B82-cancers-12-02111]\]. Upregulation of XIST in MM and glioblastoma may represent a counter regulatory mechanism balancing enhanced miR-21 expression.

Downregulated expression of the tumor suppressor lncRNA *maternally expressed gene 3* (MEG3) promotes MM growth and metastasis \[[@B58-cancers-12-02111]\]. Thereby, lncRNA MEG3 functions as a sponge of miR-21 \[[@B58-cancers-12-02111]\]. Downregulated lncRNA MEG3 increased miR-21 associated with suppressed expression of E-cadherin, a newly recognized epigenetic target of miR-21 \[[@B58-cancers-12-02111]\]. Notably, increased expression of lncRNA MEG3 has also been reported in gliomas \[[@B83-cancers-12-02111]\].

LncRNA *growth arrest-specific transcript 5* (GAS5) inhibits the migration and invasion of MM cells \[[@B84-cancers-12-02111]\]. Expression of GAS5 is downregulated in MM tissues compared to adjacent normal tissues \[[@B85-cancers-12-02111]\]. Lentiviral-mediated overexpression of lncRNA GAS5 reduces invasion activity in human MM cells \[[@B86-cancers-12-02111]\]. Remarkably, lncRNA GAS5 functions as a sponge of miR-21 \[[@B87-cancers-12-02111],[@B88-cancers-12-02111]\]. In a feedback loop, miR-21 suppresses the expression of lncRNA GAS5 \[[@B89-cancers-12-02111]\]. There is an emerging interest in exosome-derived non-coding RNAs in cancer biology \[[@B90-cancers-12-02111],[@B91-cancers-12-02111]\], which might also have an impact on melanomagenesis. Taken together, lncRNAs are important epigenetic regulators of miR-21 expression ([Table 3](#cancers-12-02111-t003){ref-type="table"}).

4. Exosome-Mediated MiR-21 Transport {#sec4-cancers-12-02111}
====================================

4.1. Exosome-Mediated Transfer of MiR-21 to Melanocytic Lesions {#sec4dot1-cancers-12-02111}
---------------------------------------------------------------

MiR-21 in MM cells is either synthesized intracellularly or transferred from the tissue environment by miR-21-enriched exosomes that recently gained high interest within the pathogenesis of various skin diseases including MM \[[@B96-cancers-12-02111],[@B97-cancers-12-02111]\]. Exosomes are extracellular vesicles (EVs) of endocytic and secretory exocytic origin that mediate three-dimensional communication between cells. Exosomes transport cellular components such as miRs, mRNAs, lncRNAs, circular RNAs, proteins and DNAs. They are secreted into body fluids by multiple cell types, including keratinocytes, fibroblasts, adipocytes, benign melanocytes and MM cells. MM-derived exosomes contain intact and functional mRNAs, small RNAs (including miR-21), and proteins (PD-L1) that can alter the cellular environment to favor MM growth \[[@B98-cancers-12-02111],[@B99-cancers-12-02111]\].

The melanocyte appears in close vicinity with epidermal keratinocytes, dermal fibroblasts, subcutaneous adipocytes and immune cells that all exchange exosomes. Exosomes are a special class of EVs that represent nanoparticles of 50--180 nm in diameter. They transport increased amounts of miR-21 of bystander cells to melanocytes, especially after cellular stresses such as ultraviolet (UV) irradiation, free radicals or metabolic alterations. Increased exosomal miR-21 traffic to melanocytes may represent a widely ignored molecular mechanism promoting melanomagenesis and MM progression, which will be discussed in more detail.

4.2. Melanoma-Derived MiR-21-Enriched Exosomes and Melanoma Progression {#sec4dot2-cancers-12-02111}
-----------------------------------------------------------------------

Tumor cell-derived exosomes regulate target gene expression in normal cells \[[@B100-cancers-12-02111]\]. Exosomal miR-21 uptake results from clathrin-mediated endocytosis and macropinocytosis \[[@B100-cancers-12-02111]\]. MM cells are involved in intensive exosome traffic. They either perceive exosome signals from their environment as bystander cells or themselves secrete tumor-promoting exosomes into their environment \[[@B101-cancers-12-02111],[@B102-cancers-12-02111],[@B103-cancers-12-02111],[@B104-cancers-12-02111]\]. MM exosomes mediate pro-tumor processes including angiogenesis, immune dysregulation and modification of the tissue microenvironment \[[@B104-cancers-12-02111]\]. Metastatic MM secretes a higher exosome amount than primary MM, and acidic pH increases exosome secretion \[[@B105-cancers-12-02111]\]. MM exosome production, transfer and programming of bone marrow cells support tumor growth and metastasis \[[@B106-cancers-12-02111]\]. MM-derived exosomes induce a reprogramming of fibroblasts into cancer-associated fibroblasts (CAFs) \[[@B104-cancers-12-02111],[@B107-cancers-12-02111]\]. In accordance, glioma cells shape their microenvironment and communicate with the surrounding microglia \[[@B108-cancers-12-02111]\]. Uptake of glioma cell-derived exosomal miR-21 by microglia cells results in their reprogramming to create a favorable microenvironment for glioma progression \[[@B108-cancers-12-02111]\]. Likewise, MM cells modulate their tumor microenvironment by modulating exosome transfer \[[@B107-cancers-12-02111],[@B109-cancers-12-02111]\]. MM-derived exosomes promote epithelial-mesenchymal transition (EMT) in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment \[[@B110-cancers-12-02111]\].

Accordingly, patients with metastatic sporadic MM exhibit higher plasma exosomal miR-21 levels, when compared to familial MM or unaffected control subjects \[[@B111-cancers-12-02111]\]. Surprisingly, no substantial differences in miR-21 expression were detected between familial MM patients and unaffected controls \[[@B111-cancers-12-02111]\], pointing to a predominant role of miR-21 in sporadic MM, which is under stronger influence of environmental compared to genetic factors. Notwithstanding, copy numbers of plasma miR-21 correlate with tumor burden in MM patients \[[@B112-cancers-12-02111]\]. MiR-21 is positively correlated with the TNM stage and represents an independent risk factor for MM metastasis \[[@B37-cancers-12-02111]\]. Of interest, increased expression of miR-21 has also been detected in vitreal exosomes of patients with uveal melanoma as well as in formalin-fixed, paraffin-embedded uveal melanoma specimens \[[@B113-cancers-12-02111]\].

MiR-21 promotes tumorigenesis in MM, glioblastoma and prostate cancer via inhibition of pivotal tumor suppressors ([Figure 3](#cancers-12-02111-f003){ref-type="fig"}) \[[@B33-cancers-12-02111],[@B40-cancers-12-02111],[@B49-cancers-12-02111],[@B50-cancers-12-02111],[@B72-cancers-12-02111],[@B114-cancers-12-02111],[@B115-cancers-12-02111]\]. MiR-21 modifies the extracellular matrix by suppressing critical inhibitors of matrix metalloproteinases including TIMP3 and RECK \[[@B55-cancers-12-02111],[@B56-cancers-12-02111],[@B116-cancers-12-02111]\]. In fact, increased expression of miR-21 enhances the invasive potential of MM cells through TIMP3 inhibition \[[@B56-cancers-12-02111]\]. Furthermore, miR-21 induces tumor angiogenesis through targeting PTEN, activating AKT and ERK1/2 signaling, thereby enhancing HIF-1α and VEGF expression as well as by targeting FASLG and angiotensin II \[[@B115-cancers-12-02111],[@B117-cancers-12-02111],[@B118-cancers-12-02111],[@B119-cancers-12-02111],[@B120-cancers-12-02111]\].

4.3. Immunological Surveillance {#sec4dot3-cancers-12-02111}
-------------------------------

MM can be considered a disease of immune dysfunction with a failure of immune recognition, which is the rationale of immune-checkpoint inhibition (ICI) \[[@B121-cancers-12-02111],[@B122-cancers-12-02111]\]. ICI augments neoantigen-specific CD8+ T cell responses, resulting in tumor regression \[[@B123-cancers-12-02111]\]. Tissue-resident CD8+ memory T cells (TRM) play a vital role for host immune responses to cancer \[[@B124-cancers-12-02111]\]. Of interest, skin-resident memory T cell responses to MM are generated naturally as a result of autoimmune vitiligo \[[@B125-cancers-12-02111]\]. In the epidermis, TRM mediate anti-tumor immunity and promote an MM-immune equilibrium \[[@B125-cancers-12-02111],[@B126-cancers-12-02111]\]. Patients with high intratumoral CD8+ T cells display a higher response to BRAF or BRAF/MEK inhibitors \[[@B127-cancers-12-02111]\]. The dynamic network of miRs is of pivotal importance for the regulation of T cell responses. Intriguingly, upregulation of miR-21 biases the transcriptome of differentiating T cells away from memory T cells and toward inflammatory effector T cells \[[@B128-cancers-12-02111]\]. Such a transcriptome bias is also characteristic of T cell responses in older individuals who have increased miR-21 expression, which is reversed by antagonizing miR-21 \[[@B128-cancers-12-02111]\]. Thus, T cells with high miR-21 expression disfavor the induction of transcription factor networks involved in memory T cell differentiation, which plays a key role in the immunological surveillance of MM.

MiR-21 expression in cells of the tumor immune infiltrate, particularly macrophages, is responsible for promoting tumor growth, whereas the absence of miR-21 in tumor-associated macrophages causes a global rewiring of their transcriptional regulatory network that is skewed toward a pro-inflammatory angiostatic phenotype \[[@B129-cancers-12-02111]\]. This promotes an anti-tumoral immune response characterized by a macrophage-mediated improvement of cytotoxic T-cell responses through the induction of cytokines and chemokines \[[@B129-cancers-12-02111]\]. Moreover, miR-21 contributes to macrophage M2 reprogramming of tumor infiltrating myeloid cells (TIMs) promoting MM metastasis \[[@B130-cancers-12-02111]\]. In contrast, miR-21 deficient B16 mouse melanoma upregulate PD-L1 expression in macrophages, promote macrophage M1 polarization with anti-tumor activity \[[@B38-cancers-12-02111]\]. Of notice, miR-21 suppresses IL12A, the p35 subunit of interleukin 12 (IL-12) \[[@B59-cancers-12-02111]\]. IL-12 exhibits anti-tumor activities via regulation of both innate (natural killer cells) and adaptive (cytotoxic T lymphocytes) immunity \[[@B131-cancers-12-02111],[@B132-cancers-12-02111]\]. Several studies have addressed the use of IL-12 for melanoma therapy due to its immunoregulatory function and anti-tumor activity mediated by stimulation of T and NK effector cells \[[@B133-cancers-12-02111],[@B134-cancers-12-02111]\].

MM exosomes provoke immune suppression and defective dendritic cell (DC) functions \[[@B135-cancers-12-02111]\]. MM exosomes suppress proliferation in CD8+ T cells and downregulate *killer cell lectin-like, subfamily K, member 1* (NKG2D) expression in NK cells \[[@B136-cancers-12-02111]\]. In addition, MM cells secrete PD-L1 through exosomes, which exhibit immunosuppressive activities and inhibit T-cell activation \[[@B137-cancers-12-02111]\]. Furthermore, MM-derived exosomes downregulate T-cell responses through decreased T-cell receptor (TCR) signaling and diminish cytokine and granzyme B secretions \[[@B138-cancers-12-02111]\] ([Figure 3](#cancers-12-02111-f003){ref-type="fig"}).

4.4. MiR-21 Overexpression in Melanoma-Related Tumors {#sec4dot4-cancers-12-02111}
-----------------------------------------------------

MiR-21 is also upregulated in glioblastoma and prostate cancer \[[@B93-cancers-12-02111],[@B139-cancers-12-02111],[@B140-cancers-12-02111],[@B141-cancers-12-02111],[@B142-cancers-12-02111]\], two common cancers of Western societies that are associated with MM \[[@B143-cancers-12-02111],[@B144-cancers-12-02111],[@B145-cancers-12-02111]\]. Increased risk of prostate cancer has been associated with the occurrence of late adolescent acne \[[@B146-cancers-12-02111],[@B147-cancers-12-02111]\]. Of notice, in US women \[[@B148-cancers-12-02111]\], but not in Swedish men \[[@B149-cancers-12-02111]\], teenage acne was associated with increased MM risk. Since acne has been linked to the Western exposome comprising diet, medication, pollutants, psychosocial and other environmental and lifestyle factors \[[@B150-cancers-12-02111]\], it is conceivable that these factors also have an impact on MM via upregulation of miR-21 \[[@B151-cancers-12-02111]\].

5. Environmental Factors Upregulating MiR-21 {#sec5-cancers-12-02111}
============================================

5.1. Radiation {#sec5dot1-cancers-12-02111}
--------------

Not only ultraviolet (UV) radiation, which is today's primary focus in melanomagenesis, but also other spectra of electromagnetic radiation enhance miR-21 expression as outlined in more detail below.

### 5.1.1. Ultraviolet Irradiation {#sec5dot1dot1-cancers-12-02111}

Exposure to UV radiation from sunlight or tanning beds contributes to UV-induced DNA damage, oxidative stress, and inflammation in the skin playing a dominant role in melanomagenesis and DNA mutations causing MM \[[@B152-cancers-12-02111],[@B153-cancers-12-02111]\]. However, key mutations in MM are not UV-signature mutations (C⟶T) including the BRAF^V600E^ mutation found in 60% of MMs and NRAS mutations detected in 15--20% of MMs, respectively \[[@B154-cancers-12-02111]\]. Therefore, UV radiation alone may not explain all mutagenic effects in MMs. Notwithstanding, these non-UV-signature mutations are more common in sun-exposed skin \[[@B155-cancers-12-02111],[@B156-cancers-12-02111],[@B157-cancers-12-02111],[@B158-cancers-12-02111]\]. MMs of the head and neck are associated with chronic patterns of sun exposure, whereas trunk MMs are related to intermittent patterns of sun exposure, supporting the hypothesis that MMs may arise through divergent causal pathways \[[@B159-cancers-12-02111]\].

Intriguingly, UV radiation induces the release of keratinocyte-derived exosomes that communicate with melanocytes to regulate pigmentation \[[@B160-cancers-12-02111],[@B161-cancers-12-02111]\]. EVs released by melanocytes after UV-A irradiation promote intercellular signaling with increased miR-21 expression in keratinocytes \[[@B162-cancers-12-02111]\]. Notably, UV radiation upregulates miR-21 in keratinocytes, fibroblasts and melanocytes \[[@B163-cancers-12-02111],[@B164-cancers-12-02111],[@B165-cancers-12-02111],[@B166-cancers-12-02111],[@B167-cancers-12-02111]\]. MiR-21 enhances the expression of microphthalmia-associated transcription factor (MITF) by targeting SOX5, an inhibitor of MITF \[[@B51-cancers-12-02111]\]. MITF represents a melanocytic lineage-specific transcription factor, which plays a key role in melanomagenesis \[[@B168-cancers-12-02111]\]. Accordingly, SOX5 knockdown upregulates MITF in MM cells \[[@B52-cancers-12-02111]\]. Furthermore, miR-21 controls the DNA mismatch repair (MMR) protein MSH2, which is a crucial caretaker of the MMR including transcription-coupled repair \[[@B169-cancers-12-02111]\]. MMR deficiency is a frequent condition in MM \[[@B170-cancers-12-02111]\]. Reduced or defective expression of MSH2 has been associated with high genomic instability, poor MM prognosis, and metastasis \[[@B114-cancers-12-02111],[@B171-cancers-12-02111],[@B172-cancers-12-02111]\]. Decreased expression or function of MSH2 is either a result of mutation-derived dysfunction of MSH2 or miR-21-mediated downregulation of MSH2 \[[@B53-cancers-12-02111],[@B114-cancers-12-02111],[@B171-cancers-12-02111],[@B172-cancers-12-02111],[@B173-cancers-12-02111]\]. Thus, UV-induced generation of exosomal miR-21 with subsequent uptake of miR-21 by melanocytes may promote genetic instability and gene mutations driving melanomagenesis.

### 5.1.2. Cosmic Ionizing Irradiation {#sec5dot1dot2-cancers-12-02111}

Airline pilots and cabin crew members have about twice the risk of MM compared to the general population \[[@B174-cancers-12-02111],[@B175-cancers-12-02111]\]. Cosmic radiation primarily consists of neutrons and gamma rays allowing high linear energy transfer (LET) \[[@B176-cancers-12-02111]\], which stimulates miR-21 expression through the STAT3 pathway ([Figure 1](#cancers-12-02111-f001){ref-type="fig"}) \[[@B177-cancers-12-02111],[@B178-cancers-12-02111]\]. Ionizing radiation-induced miR-21 promotes EMT and angiogenesis by downregulation of PTEN \[[@B115-cancers-12-02111],[@B179-cancers-12-02111]\]. Notably, ionizing radiation causes bystander effects on neighboring non-irradiated cells via transfer of exosomes enriched in miR-21 \[[@B180-cancers-12-02111],[@B181-cancers-12-02111]\]. Cosmic radiation may thus upregulate miR-21 levels of epidermal keratinocytes and bystander melanocytes, a potential contribution to melanomagenesis in aircrew members.

### 5.1.3. Electromagnetic Radiation {#sec5dot1dot3-cancers-12-02111}

Aircrew members are also exposed to electromagnetic fields \[[@B182-cancers-12-02111]\]. Magnetic field levels in the cockpit have a mean value of approximately 17 milliGauss, while cabin measurements are lower \[[@B182-cancers-12-02111]\]. Remarkably, pulsed electromagnetic fields enhance miR-21 expression in human bone marrow stromal cells \[[@B183-cancers-12-02111]\]. Thus, pilots are exposed to a wide spectrum of miR-21-inducing radiation including cosmic ionizing radiation, UV-A radiation (passing through cockpit windshields \[[@B184-cancers-12-02111]\]) and electromagnetic fields in the cockpit including radio transmission.

A correlation between frequency modulation radio transmitter density and MM incidence has been reported in a study involving 23 European countries \[[@B185-cancers-12-02111]\]. Of notice, pilots also have a higher risk for glioma \[[@B186-cancers-12-02111],[@B187-cancers-12-02111]\]. An association of MM and glioma risk has also been observed in the general population \[[@B143-cancers-12-02111]\], which may be linked to their common progenitors of neural crest-derived glia cells and melanoblasts \[[@B188-cancers-12-02111]\]. Recently, an association between mobile phone use and low-grade glioma has been reported \[[@B189-cancers-12-02111],[@B190-cancers-12-02111]\], whereas a cohort study in Denmark found no significant association between mobile phone use (another source of electromagnetic radiation) and MM \[[@B191-cancers-12-02111]\]. Thus, translational evidence suggests that not only UV, but a much wider spectrum of electromagnetic radiation upregulates the expression of miR-21 that may affect MM and glioma development via exosomal miR-21 transfer.

5.2. Metabolic Deviations Upregulating MiR-21 {#sec5dot2-cancers-12-02111}
---------------------------------------------

### 5.2.1. Metabolic Syndrome and Melanoma Risk {#sec5dot2dot1-cancers-12-02111}

An important contributor to the pandemic of cardiovascular disease is overweight, obesity, insulin resistance, type 2 diabetes mellitus (diabesity), and arterial hypertension, major components of the metabolic syndrome \[[@B192-cancers-12-02111],[@B193-cancers-12-02111]\]. Diabesity is associated with changes in the maternal environment, which can affect developmental processes \[[@B194-cancers-12-02111]\]. Recently, glioma progression has been related to diabesity \[[@B195-cancers-12-02111]\]. There is compelling epidemiological evidence that increased birth weight (BW) is associated with an increased risk of obesity and type 2 diabetes mellitus (T2DM) \[[@B196-cancers-12-02111],[@B197-cancers-12-02111],[@B198-cancers-12-02111]\]. Notably, high BW (\>4000 g) was associated with increased risk of obesity \[[@B196-cancers-12-02111]\]. Especially, early development of obesity predicted obesity in adulthood, predominantly for children who were severely obese \[[@B199-cancers-12-02111]\]. In the United States, the 2017 incidence of fetal macrosomia, defined as BW \>4000 g, was 8.07% \[[@B200-cancers-12-02111]\]. In a murine model, fetal macrosomia has been identified as an independent risk factor of the metabolic syndrome \[[@B201-cancers-12-02111]\]. Intriguingly, fetal and childhood growth trajectories are not only linked to an increased risk of the metabolic syndrome but also of MM as outlined below.

### 5.2.2. Birth Weight and Height in Childhood {#sec5dot2dot2-cancers-12-02111}

A case-control study of 1396 cases of MM diagnosed before the age of 30 in 1988--2013 and 27,920 controls in California demonstrated that high BW (\>4000 g) compared to normal BW is associated with a 19% higher risk for MM before the age of 30 \[[@B202-cancers-12-02111]\]. In placental tissue of macrosomic babies, increased levels of miR-21 have been detected \[[@B203-cancers-12-02111],[@B204-cancers-12-02111]\]. Placental-derived exosomes and their miR cargo are related to pregnancy complications \[[@B205-cancers-12-02111],[@B206-cancers-12-02111]\] and may also have an impact on melanomagenesis during the fetal growth period.

Height at ages 7--13 years can also affect MM risk, according to data from the Copenhagen School Health Records Register \[[@B207-cancers-12-02111]\]. A positive association between genetically-predicted height and MM risk has also been observed \[[@B208-cancers-12-02111]\]. Of relevance, cow's milk consumption during childhood has been associated with increased linear growth \[[@B209-cancers-12-02111]\]. Exosome transfer of bovine milk miR-21 \[[@B210-cancers-12-02111]\], which is identical to human miR-21, increases mTORC1 signaling \[[@B211-cancers-12-02111],[@B212-cancers-12-02111],[@B213-cancers-12-02111],[@B214-cancers-12-02111],[@B215-cancers-12-02111],[@B216-cancers-12-02111],[@B217-cancers-12-02111],[@B218-cancers-12-02111],[@B219-cancers-12-02111]\]. Activated mTORC1 promotes osteogenesis and myogenesis \[[@B216-cancers-12-02111],[@B217-cancers-12-02111]\] and plays a key role in acne and BRAF^V600E^-related MM \[[@B214-cancers-12-02111],[@B215-cancers-12-02111],[@B218-cancers-12-02111]\]. Thus, accelerated growth in the fetal period and during childhood is related to excessive miR-21/mTORC1 signaling that may also affect melanomagenesis.

### 5.2.3. Overweight and Obesity {#sec5dot2dot3-cancers-12-02111}

Recent studies support a link between obesity and MM occurrence and progression \[[@B220-cancers-12-02111],[@B221-cancers-12-02111],[@B222-cancers-12-02111],[@B223-cancers-12-02111],[@B224-cancers-12-02111],[@B225-cancers-12-02111]\]. Studies with the 3T3-L1 adipocyte cell line as well as ex vivo subcutaneous and visceral adipose tissue conditioned medium have shown that adipocyte-released factors increase MM cell overall survival \[[@B226-cancers-12-02111]\]. Adipocyte-derived conditioned media activate AKT and mTORC1 in MM cells and stimulate proliferation, migration, and invasion \[[@B227-cancers-12-02111]\]. In addition, adipocyte-derived exosomes promote MM aggressiveness by increasing fatty acid oxidation \[[@B228-cancers-12-02111],[@B229-cancers-12-02111]\]. Interestingly, high-fat diet (HFD)-induced obesity in mice increases miR-21 content of white adipose tissue and upregulates the proliferation of human adipose tissue-derived mesenchymal stem cells \[[@B230-cancers-12-02111],[@B231-cancers-12-02111]\]. Exosomes released from adipocyte-derived stem cells exhibit elevated miR-21 levels that induce angiogenesis through AKT and ERK activation and enhance the migration and proliferation of HaCaT cells \[[@B232-cancers-12-02111],[@B233-cancers-12-02111]\]. Moreover, the adipokine leptin promotes MM growth and activates STAT3 \[[@B220-cancers-12-02111],[@B234-cancers-12-02111],[@B235-cancers-12-02111]\], which induces miR-21 expression ([Figure 1](#cancers-12-02111-f001){ref-type="fig"}) ([Table 3](#cancers-12-02111-t003){ref-type="table"}) \[[@B229-cancers-12-02111],[@B235-cancers-12-02111]\]. In mature human adipocytes, miR-21 is also upregulated by tumor necrosis factor-α (TNF-α), IL-6, resistin and free fatty acids (FFAs) \[[@B236-cancers-12-02111]\]. Apparently, adipocytes of obese individuals secrete miR-21-enriched exosomes into the microenvironment of melanocytes and into the systemic circulation ([Figure 3](#cancers-12-02111-f003){ref-type="fig"}). Cancer-associated adipocytes (CAAs) release FFAs, which are transferred to cancer cells and are used for energy production through β-oxidation \[[@B237-cancers-12-02111]\]. As FFAs induce the expression of miR-21 \[[@B236-cancers-12-02111]\], upregulation of miR-21 in CAA-derived exosomes is expected. In fact, peritumoral CAAs isolated from the omental adipose tissue surrounding metastatic ovarian cancer secrete miR-21-enriched exosomes, which are transferred to cancer cells \[[@B238-cancers-12-02111]\]. Thus, epigenetic evidence indicates that exosomal transfer of miR-21 by adipocytes of obese individuals and CAAs may promote melanomagenesis.

### 5.2.4. Diabetes Mellitus {#sec5dot2dot4-cancers-12-02111}

A recent meta-analysis reported an increased risk of MM in patients with T2DM \[[@B239-cancers-12-02111]\]. Moreover, miR-21 is increased in the blood of T2DM patients \[[@B240-cancers-12-02111],[@B241-cancers-12-02111],[@B242-cancers-12-02111]\]. In a diabetic mouse model, the curcumin analog C66 inhibits diabetes-related induction of miR-21 in analogy to miR-21 reductions by locked nucleic acid-modified anti-miR-21 (LNA-21) \[[@B243-cancers-12-02111]\]. Thus, overexpressed miR-21 in T2DM might represent a molecular link between T2DM and MM.

In type 1 diabetes mellitus (T1DM), 𝛽-cell-derived exosomal miR-21 cargo significantly increased in response to inflammatory cytokines \[[@B244-cancers-12-02111]\], therefore T1DM might also be implicated in melanomagenesis, especially in the context of chronic inflammation.

### 5.2.5. Arterial Hypertension {#sec5dot2dot5-cancers-12-02111}

An association between arterial hypertension and MM risk has been reported \[[@B245-cancers-12-02111],[@B246-cancers-12-02111],[@B247-cancers-12-02111]\]. The mechanisms of this interaction are yet unknown. A potential link is the recent observation of increased circulatory levels of miR-21 in patients with hypertensive heart disease \[[@B92-cancers-12-02111]\]. Suppression of miR-21 prevents hypertrophic stimulation-induced cardiac remodeling by regulating PDCD4, AP-1, and TGF-β1 signaling pathways \[[@B92-cancers-12-02111]\].

### 5.2.6. Western Diet {#sec5dot2dot6-cancers-12-02111}

Western diet might may also drive melanomagenesis \[[@B151-cancers-12-02111],[@B248-cancers-12-02111]\]. For instance, the chronic consumption of hyperpalatable processed foods high in sugar, fat, salt, and flavor additives can lead to excessive energy intake and obesity \[[@B249-cancers-12-02111]\]. It has been demonstrated in mouse models, that diet-induced obesity directly increases MM initiation and progression \[[@B220-cancers-12-02111],[@B250-cancers-12-02111]\]. Furthermore, a high intake of sugars, mostly sucrose, glucose and fructose, has been identified as a potential risk factor of MM in a recent Italian study \[[@B251-cancers-12-02111]\]. An overall high glycemic load (GL) has been associated with increased risk of MM and acne \[[@B252-cancers-12-02111],[@B253-cancers-12-02111]\]. Of notice, high GL diets might overactivate mTORC1, particularly under the context of positive energy balance \[[@B203-cancers-12-02111],[@B254-cancers-12-02111]\]. In response to high glucose intake, endothelial cells overexpress miR-21 \[[@B255-cancers-12-02111]\]. In addition, high glucose-stimulated expression of miR-21 inactivates PRAS40, a negative regulator of mTORC1 \[[@B60-cancers-12-02111]\]. Fructose can also increase plasma levels of miR-21 \[[@B256-cancers-12-02111]\].

It has been suggested to replace this unfavorable dietary pattern by low-carbohydrate high-fat ketogenic diets \[[@B257-cancers-12-02111],[@B258-cancers-12-02111]\], but these might negatively impact MM \[[@B258-cancers-12-02111],[@B259-cancers-12-02111],[@B260-cancers-12-02111]\]. For instance, oncogenic BRAF^V600E^ upregulates HMG-CoA lyase, which converts HMG-CoA to acetyl-CoA and the ketone body acetoacetate, that selectively enhances BRAF^V600E^-dependent MEK1 activation in MM \[[@B261-cancers-12-02111]\]. A high-fat ketogenic diet increases serum levels of acetoacetate leading to enhanced growth of BRAF^V600E^-expressing human MM cells in xenograft mice \[[@B262-cancers-12-02111]\]. Notably, BRAF^V600E^ is negatively controlled by members of the Sprouty family of tumor suppressors \[[@B262-cancers-12-02111]\], which are targets of miR-21 \[[@B40-cancers-12-02111],[@B42-cancers-12-02111],[@B151-cancers-12-02111]\]. It is thus conceivable that miR-21-mediated downregulation of Sprouty enhances BRAF^V600E^-driven MM growth ([Figure 2](#cancers-12-02111-f002){ref-type="fig"}).

There is recent interest in exosomes derived from foods \[[@B263-cancers-12-02111],[@B264-cancers-12-02111]\], particularly those delivered by pasteurized milk \[[@B212-cancers-12-02111]\]. Milk consumption might affect MM through activation of mTORC1 signaling due to its amino acid profile and endocrine effects (increase of insulin-like growth factor 1) and by transfer of miR-21-enriched milk exosomes to the milk consumer \[[@B210-cancers-12-02111],[@B211-cancers-12-02111],[@B212-cancers-12-02111],[@B213-cancers-12-02111]\]. Indeed, in mice, orally administered cow's milk exosomes are bioavailable, distribute in various tissues and organs and affect metabolic regulation \[[@B265-cancers-12-02111],[@B266-cancers-12-02111]\]. Moreover, consumption of milk fat, which is also a rich source of miR-21 \[[@B267-cancers-12-02111]\], enhances telomere length \[[@B268-cancers-12-02111]\]. Interestingly, miR-21 via inhibiting PTEN activates telomerase (hTERT) \[[@B269-cancers-12-02111],[@B270-cancers-12-02111]\], which is a further feature of MM \[[@B271-cancers-12-02111],[@B272-cancers-12-02111]\].

Western diets are also characterized by excessive intake of alcohol \[[@B273-cancers-12-02111]\], which can impact MM \[[@B274-cancers-12-02111]\]. Chronic alcohol intake, especially in combination with HFD results in persistent ketonuria associated with increased serum levels of acetoacetate \[[@B275-cancers-12-02111]\], which accelerates BRAF^V600E^-MEK1 signaling. Furthermore, excessive alcohol consumption combined with acute psychological stress upregulates miR-21 \[[@B276-cancers-12-02111],[@B277-cancers-12-02111]\].

Dietary xenobiotics, present in the Western diet, may also impact MM. For instance, chronic exposure to polychlorinated biphenyls (PCBs), mainly from fatty fish, are associated with a four-fold increased risk of MM \[[@B278-cancers-12-02111]\], perhaps because PCBs increase miR-21 expression \[[@B279-cancers-12-02111],[@B280-cancers-12-02111]\]. Finally, Western diets trigger inflammation \[[@B281-cancers-12-02111]\], which is critically involved in melanomagenesis, as outlined below.

### 5.2.7. Smoking and Pollution {#sec5dot2dot7-cancers-12-02111}

Smoking has recently been identified in some studies as a predictor of poor MM outcome \[[@B282-cancers-12-02111],[@B283-cancers-12-02111]\], whereas other studies found no or even inverse relations between smoking and MM incidence \[[@B284-cancers-12-02111],[@B285-cancers-12-02111],[@B286-cancers-12-02111]\]. In contrast to these conflicting epidemiological studies, molecular evidence appears to be more consistent. For example, nicotine induces the expression of miR-21 and promotes EMT in esophageal cells \[[@B287-cancers-12-02111]\]. Cigarette smoke induces the release of miR-21-enriched exosomes from bronchial epithelial cells \[[@B288-cancers-12-02111]\]. Exosomes released from nicotine-stimulated macrophages increase miR-21/PTEN-mediated vascular smooth muscle cell migration and proliferation \[[@B289-cancers-12-02111]\].

Pollution may also affect MM. In a study with human bronchial epithelial cells, diesel exhaust particles increased miR-21 expression and activated the PI3K/AKT pathway \[[@B290-cancers-12-02111]\]. Possibly, smoke- and pollution-induced airway epithelial cell-derived exosomes may enter the systemic circulation promoting melanomagenesis ([Figure 4](#cancers-12-02111-f004){ref-type="fig"}).

5.3. Hormonal Factors {#sec5dot3-cancers-12-02111}
---------------------

### 5.3.1. Androgens {#sec5dot3dot1-cancers-12-02111}

Accumulating epidemiological evidence associates prostate cancer, acne and MM \[[@B144-cancers-12-02111],[@B145-cancers-12-02111],[@B148-cancers-12-02111],[@B291-cancers-12-02111]\], with androgen-dependence as a possible link \[[@B291-cancers-12-02111]\]. Indeed, the promotor of *MIR21* is upregulated by androgen receptor (AR) ([Table 3](#cancers-12-02111-t003){ref-type="table"}) \[[@B93-cancers-12-02111]\]. Notably, patients with AR-positive MM have worse survival outcomes compared to patients with AR-negative MM \[[@B292-cancers-12-02111]\]. AR also promotes MM metastasis via MITF signaling \[[@B292-cancers-12-02111]\]. In accordance, dehydroepiandrosterone (DHEA), often administered for anti-aging purposes \[[@B293-cancers-12-02111]\], also upregulates the transcription of miR-21 \[[@B294-cancers-12-02111]\].

### 5.3.2. Growth Hormone {#sec5dot3dot2-cancers-12-02111}

Human metastatic MM cell lines express high levels of growth hormone receptor (GHR) and respond to GH with increased proliferation \[[@B295-cancers-12-02111]\]. GH promotes, while GHR knockdown attenuates MM progression \[[@B296-cancers-12-02111]\]. GH affects multiple oncogenic signaling pathways, especially JAK2-STAT3 \[[@B296-cancers-12-02111]\]. The GH-GHR axis induces chemoresistance in human MM by driving MITF-regulated and ABC-transporter-mediated drug clearance pathways \[[@B297-cancers-12-02111]\]. Increased GH-JAK2-STAT3 signaling may thus explain the association between GH administration and MM ([Figure 2](#cancers-12-02111-f002){ref-type="fig"}) \[[@B298-cancers-12-02111],[@B299-cancers-12-02111],[@B300-cancers-12-02111]\]. Interestingly, the prepubertal somatotropic axis can be modified by milk consumption \[[@B301-cancers-12-02111],[@B302-cancers-12-02111]\]. Daily milk consumption in 10- to 11-year-old children increases their plasma GH levels and accelerates their longitudinal growth \[[@B302-cancers-12-02111]\]. This is of concern because height at ages 7--13 years significantly increases MM risk \[[@B209-cancers-12-02111]\]. Elevated GH plasma levels have also been observed after ingestion of gelatin protein, soy protein, and α-lactalbumin, a whey protein \[[@B303-cancers-12-02111]\]. Of notice, recombinant GH is frequently abused in combination with androgens and whey protein supplements to gain muscle mass \[[@B304-cancers-12-02111]\], a doping procedure that may increase MM risk.

### 5.3.3. Vitamin D {#sec5dot3dot3-cancers-12-02111}

Vitamin D (VD) deficiency has been associated with a poorer outcome in MM \[[@B282-cancers-12-02111],[@B283-cancers-12-02111]\], and has been correlated with BRAF-mutated MM \[[@B305-cancers-12-02111]\]. Higher 25-hydroxyvitamin D~3~ (25OHD~3~) levels are associated with lower Breslow thickness at diagnosis and are independently protective of relapse and death of MM \[[@B306-cancers-12-02111]\], whereas patients with low 25OHD~3~ concentrations are associated with greater Breslow thickness and reduced survival \[[@B307-cancers-12-02111],[@B308-cancers-12-02111]\]. Clinicopathological analyses have shown positive correlations between low or undetectable expression of VD receptor (VDR) in MM with accelerated tumor progression \[[@B308-cancers-12-02111],[@B309-cancers-12-02111]\]. Notably, VD upregulates the expression of programmed death ligand 1 (PD-L1) on both epithelial and immune cells, suggesting an interaction with immune checkpoint inhibitors \[[@B310-cancers-12-02111]\]. Intriguingly, VDR inhibits the expression of miR-21 \[[@B54-cancers-12-02111],[@B94-cancers-12-02111],[@B95-cancers-12-02111],[@B311-cancers-12-02111],[@B312-cancers-12-02111]\]. Furthermore, the expression of the miR-processing ribonuclease DICER1 positively correlates with VD metabolite levels \[[@B311-cancers-12-02111]\]. MiR-21 negatively regulates VD production through inhibition of CYP27B1 encoding 25OHD~3~-1-α-hydrolase, which converts 25OHD~3~ to its active form, 1α,25-dihydroxyvitamin D~3~ (1α,25-\[OH\]~2~D~3~) \[[@B54-cancers-12-02111]\]. The recently observed correlation between BRAF^V600E^ mutation status and VD deficiency may thus be explained by BRAF^V600E^ mutation-induced overexpression of CYP24A1, encoding 24-hydroxylase \[[@B313-cancers-12-02111]\], the mitochondrial enzyme responsible for inactivating VD metabolites through the C-24 oxidation pathway \[[@B314-cancers-12-02111]\]. Compared to normal epidermis, highest mean CYP24A1 levels were found in nevi and early stage MMs \[[@B315-cancers-12-02111]\]. Thus, miR-21 signaling is closely related to VD homeostasis. Interestingly, UV radiation induces the synthesis of various other photoproducts that may have anti-MM activity \[[@B316-cancers-12-02111],[@B317-cancers-12-02111],[@B318-cancers-12-02111],[@B319-cancers-12-02111]\]. This, together with VD, may offer a partial explanation for the puzzling lower incidence of MM in outdoor workers and individuals with higher annual UV exposure \[[@B320-cancers-12-02111]\].

5.4. Aging and Chronic Inflammation {#sec5dot4-cancers-12-02111}
-----------------------------------

### 5.4.1. Aging {#sec5dot4dot1-cancers-12-02111}

The incidence of MM increases with age \[[@B321-cancers-12-02111],[@B322-cancers-12-02111],[@B323-cancers-12-02111]\]. Whereas MM development in younger patients is the result of genetic factors, particularly related to multiple nevi, in older patients, environmental factors play a predominant role \[[@B322-cancers-12-02111]\]. Higher age leads to worse survival in stages I, II and III \[[@B323-cancers-12-02111]\]. Remarkably, plasma levels of miR-21 increase with age \[[@B324-cancers-12-02111],[@B325-cancers-12-02111]\] and reach highest levels at the age of 66 years \[[@B324-cancers-12-02111]\], coinciding with the climax of MM incidence.

### 5.4.2. Chronic Inflammation {#sec5dot4dot2-cancers-12-02111}

Certain pro-inflammatory environmental and lifestyle factors promote cancer \[[@B281-cancers-12-02111],[@B326-cancers-12-02111]\] through nuclear factor-κB (NF-κB) and STAT3 signaling pathways \[[@B327-cancers-12-02111],[@B328-cancers-12-02111]\]. Furthermore, miR-21 activates the NLRP3 inflammasome \[[@B329-cancers-12-02111],[@B330-cancers-12-02111]\]. Increased expression of miR-21 and exosomal miR-21 is associated with inflammation in various conditions, such as diabetes mellitus (type 1 and 2), chronic renal fibrosis, and atopic diseases \[[@B331-cancers-12-02111],[@B332-cancers-12-02111],[@B333-cancers-12-02111]\]. Chronic inflammation may thus enhance the systemic burden of exosomal miR-21 that may reach the skin promoting melanomagenesis ([Table 4](#cancers-12-02111-t004){ref-type="table"}).

6. Therapeutic Suppression of MiR-21 {#sec6-cancers-12-02111}
====================================

6.1. Vemurafenib {#sec6dot1-cancers-12-02111}
----------------

MiR-21 could be a new target for the prevention and treatment of MM. Currently, the treatment of BRAF^V600^-mutated metastatic melanoma with BRAF inhibitors gives a response rate of about 50% with a progression-free survival in the range of 6--7 months \[[@B336-cancers-12-02111]\]. In vemurafenib-treated metastatic MM patients, a significant decrease in miR-21 expression was observed in BRAF-mutated in comparison with BRAF wild-type patients \[[@B336-cancers-12-02111]\]. Thus, MEK-ERK kinase inhibition in MM may attenuate miR-21 expression. In contrast, vemurafenib significantly increased total RNA and protein content of released EVs of MM cells associated with a significant increase of miR-211, which reduces the sensitivity of MM cells to vemurafenib \[[@B337-cancers-12-02111]\].

6.2. Metformin {#sec6dot2-cancers-12-02111}
--------------

The antidiabetic drug metformin decreases the risk of various cancers including MM \[[@B338-cancers-12-02111]\]. Metformin reduces MM cell growth in vitro and in rodent models \[[@B339-cancers-12-02111],[@B340-cancers-12-02111],[@B341-cancers-12-02111]\]. Whereas a recent pilot study indicates no benefit of metformin monotherapy in MM \[[@B342-cancers-12-02111]\], improved MM outcomes have been reported when metformin was combined with targeted or immune-checkpoint therapy of MM with anti-PD-1/anti-CTLA-4 \[[@B343-cancers-12-02111],[@B344-cancers-12-02111]\]. Metformin suppresses MM cell growth and motility through modulation of miR expression \[[@B345-cancers-12-02111]\]. Metformin reduces STAT3 activity in cancer cells and CSCs including glioblastoma and MM \[[@B346-cancers-12-02111],[@B347-cancers-12-02111],[@B348-cancers-12-02111]\]. Metformin-mediated STAT3 suppression explains its inhibitory effect on miR-21 \[[@B349-cancers-12-02111],[@B350-cancers-12-02111],[@B351-cancers-12-02111]\]. Metformin treatment in T2DM patients significantly reduces plasma levels of miR-21 and reduces miR-21 expression of CSCs \[[@B352-cancers-12-02111],[@B353-cancers-12-02111]\].

6.3. Beta-Blocker {#sec6dot3-cancers-12-02111}
-----------------

Beta-adrenoceptors (B~1--2~-AR) have emerged as novel targets to inhibit tumor growth and dissemination in cutaneous and uveal MM \[[@B354-cancers-12-02111],[@B355-cancers-12-02111],[@B356-cancers-12-02111]\]. Beta-blocker use correlates with better overall survival in metastatic MM, protects patients from disease recurrence and improves the efficacy of immunotherapies in mice \[[@B354-cancers-12-02111],[@B355-cancers-12-02111],[@B356-cancers-12-02111]\]. Catecholamine stimulation of B~1-2~-AR via activation of STAT3 upregulates miR-21 expression \[[@B357-cancers-12-02111],[@B358-cancers-12-02111],[@B359-cancers-12-02111],[@B360-cancers-12-02111],[@B361-cancers-12-02111],[@B362-cancers-12-02111],[@B363-cancers-12-02111],[@B364-cancers-12-02111]\], whereas beta-blocker treatment attenuates miR-21 expression \[[@B364-cancers-12-02111]\]. Beta-blocker-mediated reduction of miR-21 expression may also explain their anti-angiogenic effects in infantile hemangioma \[[@B365-cancers-12-02111]\].

6.4. Anti-MiR-21 {#sec6dot4-cancers-12-02111}
----------------

Direct targeting miR-21 has been suggested as a novel strategy for the treatment of cutaneous MM \[[@B33-cancers-12-02111]\]. Anti-miR-21 mesyl phosphoramidate oligodeoxynucleotide specifically decreases miR-21 in melanoma B16 cells, induces apoptosis, reduces proliferation, and impedes migration of tumor cells \[[@B366-cancers-12-02111]\]. Catalytic knockdown of miR-21 by artificial ribonuclease is another new option for tumors overexpressing miR-21 \[[@B367-cancers-12-02111]\]. Adeno-associated viral vectors that preferentially express antisense miR against miR-21 has therapeutic efficacy in vivo in various cancer including glioblastoma \[[@B368-cancers-12-02111]\]. Furthermore, miR-21 inhibitor and doxorubicin loaded nanometer (DLN) exert a favorable anti-cancer effect compared with single application of DLN or miR-21 inhibitor, respectively \[[@B369-cancers-12-02111]\]. Of interest, miR-21 antisense oligonucleotide decreased IC50 and increased cisplatin sensitivity for A375 melanoma cells and A375/CDDP cells, which shows that miR-21 is a new target of MM treatment \[[@B370-cancers-12-02111]\]. Furthermore, co-delivery of anti-miR-21 with doxorubicin prodrug by high-density lipoprotein-mimicking nanoparticles exerted a synergistic effect against drug resistance in cancer cells \[[@B371-cancers-12-02111]\]. In accordance, co-delivery of 5-fluorouracil (5-FU) and miR-21 inhibitor oligonucleotide (miR-21i) with engineered exosomes to colorectal cancer cells (HCT-1165FR) significantly down-regulated miR-21, induced cell cycle arrest, reduced tumor proliferation, increased apoptosis and rescued PTEN and hMSH2 expressions, regulatory targets of miR-21 \[[@B372-cancers-12-02111]\]. The combined delivery of miR-21i and 5-FU with engineered exosomes effectively reversed drug resistance and significantly enhanced the cytotoxicity in 5-FU-resistant colon cancer cells, compared with the single treatment with either miR-21i or 5-FU \[[@B372-cancers-12-02111]\]. Recent studies support the combination of miR-21 inhibition and immune checkpoint blockade to target the MM microenvironment \[[@B38-cancers-12-02111]\]. Thus, the application of exosomes loaded with anti-miR-21 may exert beneficial effects in the treatment of MM.

6.5. Interferons {#sec6dot5-cancers-12-02111}
----------------

Pegylated interferon-α (IFNα), as studied in the European Organisation for Research and Treatment of Cancer (EORTC) 18991 trial, in patients with stage III MM significantly reduced the risk of relapse (HR 0.87), however showed no impact on overall survival \[[@B373-cancers-12-02111]\]. Treatment of dendritic cells (DCs) with IFNα-2b significantly upregulates surface expression of PD-L1 molecules and reduces the capacity to stimulate interferon-γ (IFN-γ) production in T cells compared to control DCs \[[@B374-cancers-12-02111]\]. IFNα regulates PD-L1 expression through the STAT3 and p38 signaling pathways, since blocking of STAT3 and p38 activation with specific inhibitors prevents PD-L1 upregulation \[[@B374-cancers-12-02111]\]. B16 mouse MM cells treated with IFNα (1000 IU/mL, for 6 h) exhibit a significant upregulation of miR-21 expression \[[@B69-cancers-12-02111]\]. A miR microarray analysis confirmed that IFN-γ also upregulates miR-21 expression in A375 melanoma cells \[[@B375-cancers-12-02111]\]. Thus, IFN treatment of metastatic MM has an undesirable impact on miR-21 expression.

6.6. High-Intensity Focused Ultrasound {#sec6dot6-cancers-12-02111}
--------------------------------------

High-intensity focused ultrasound (HIFU), a potential noninvasive treatment procedure for solid tumors, suppresses miR-21 expression, cell migration and metastasis in a murine MM model \[[@B376-cancers-12-02111]\]. HIFU may disintegrate exosome membranes or disturb exosomal miR-21 traffic.

6.7. Iontophoretic Co-Delivery of STAT3 siRNA and Imatinib {#sec6dot7-cancers-12-02111}
----------------------------------------------------------

Effective MM suppression has also been reported by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles \[[@B377-cancers-12-02111]\]. It is conceivable that this regimen might also attenuate miR-21 expression. Low expression of lncRNA MEG3 was associated with imatinib resistance and high miR-21 expression in chronic myeloid leukemia \[[@B378-cancers-12-02111]\].

6.8. Curcumin {#sec6dot8-cancers-12-02111}
-------------

Curcumin, a natural compound derived from *Curcuma longa*, exerts anti-cancer properties, observed also in MM \[[@B379-cancers-12-02111],[@B380-cancers-12-02111]\]. The pharmacological activity of curcumin is mediated by suppression of JAK2/STAT3 signaling, which induces miR-21 expression. In addition, curcumin inhibits NF-κB and directly binds to AP-1 at the *MIR21* promoter, thereby inhibiting AP-1-dependent expression of miR-21 \[[@B380-cancers-12-02111],[@B381-cancers-12-02111],[@B382-cancers-12-02111],[@B383-cancers-12-02111]\].

6.9. Sulforaphane {#sec6dot9-cancers-12-02111}
-----------------

Sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, when orally administered in broccoli sprout extract form, is well tolerated up to 200 μmol/day and dose-dependently increases SFN levels in plasma and skin of patients with atypical nevi and/or a prior history of MM \[[@B384-cancers-12-02111]\]. In human MM cells, SFN causes cell cycle growth arrest and induces apoptosis \[[@B385-cancers-12-02111],[@B386-cancers-12-02111],[@B387-cancers-12-02111]\]. Moreover, SFN is a potent histone deacetylase inhibitor, which via epigenetic mechanisms reduces miR-21 expression \[[@B388-cancers-12-02111],[@B389-cancers-12-02111]\].

6.10. Epigallocatechin-3-Gallate {#sec6dot10-cancers-12-02111}
--------------------------------

Epigallocatechin-3-gallate (EGCG), from *Camellia sinensis*, suppresses MM cell growth and metastasis \[[@B390-cancers-12-02111],[@B391-cancers-12-02111],[@B392-cancers-12-02111],[@B393-cancers-12-02111],[@B394-cancers-12-02111]\]. Its anti-inflammatory and anti-proliferative activity is related to its suppressive effect on NF-κB and AP-1 \[[@B395-cancers-12-02111],[@B396-cancers-12-02111]\], as a potential explanation for its suppressive effect on miR-21 expression \[[@B397-cancers-12-02111],[@B398-cancers-12-02111]\].

6.11. Vitamin D {#sec6dot11-cancers-12-02111}
---------------

As outlined above, VD deficiency is related to poorer survival in metastatic MM \[[@B282-cancers-12-02111],[@B283-cancers-12-02111]\]. Enhanced VDR signaling may reduce the expression of oncogenic miR-21 \[[@B54-cancers-12-02111],[@B94-cancers-12-02111],[@B95-cancers-12-02111],[@B307-cancers-12-02111],[@B308-cancers-12-02111],[@B309-cancers-12-02111],[@B310-cancers-12-02111],[@B311-cancers-12-02111],[@B312-cancers-12-02111]\]. Nevertheless, VD supplementation for MM prevention and adjuvant therapy is still controversial \[[@B310-cancers-12-02111],[@B399-cancers-12-02111],[@B400-cancers-12-02111],[@B401-cancers-12-02111],[@B402-cancers-12-02111]\], but has been recommended in a recent vitamin D symposium \[[@B403-cancers-12-02111]\].

6.12. Exercise {#sec6dot12-cancers-12-02111}
--------------

A population-based study of 1.44 million Americans and Europeans suggested that leisure time physical activity is associated with a slightly higher risk of MM \[[@B404-cancers-12-02111]\], though other studies have found an inverse relationship \[[@B405-cancers-12-02111],[@B406-cancers-12-02111]\]. These studies are likely confounded by sun exposure. Several studies have shown that exercise has several anti-cancer effects \[[@B407-cancers-12-02111]\]. In accordance, hormone therapy plus interval training significantly reduced tumor size and miR-21 levels in a murine breast tumor model \[[@B334-cancers-12-02111]\]. Interestingly, 12 weeks of endurance training led to a significant decrease of miR-21 plasma levels in humans \[[@B335-cancers-12-02111]\] ([Table 5](#cancers-12-02111-t005){ref-type="table"}).

7. Conclusions and Perspectives {#sec7-cancers-12-02111}
===============================

Scientific interest in oncogenic dysregulation of MM focuses mainly on DNA base mutations \[[@B408-cancers-12-02111],[@B409-cancers-12-02111],[@B410-cancers-12-02111],[@B411-cancers-12-02111]\], primarily driven by UV-induced DNA damage \[[@B412-cancers-12-02111]\]. In this review, translational and epidemiological evidence underlines that not only DNA base mutations, but also miR-21-mediated epigenetic alterations enhance NRAS, BRAF and downstream MEK-ERK and AKT-mTORC1 signaling in MM ([Figure 2](#cancers-12-02111-f002){ref-type="fig"}). Notably, miR-21 via targeting a variety of tumor suppressors activates proliferation pathways promoted by common MM gene mutations. There is accumulating evidence that miR-21 levels in melanocytes and MM cells are not only regulated by endogenous synthesis but also by exogenous transfer of miR-21-enriched exosomes secreted by various cells of the MM microenvironment as well as exosomes of the systemic circulation ([Figure 4](#cancers-12-02111-f004){ref-type="fig"}). Environmental and metabolic factors including UV, ionizing and electromagnetic radiation, electromagnetic irradiation, diet, smoking, air pollution and individual factors including birth weight, growth trajectories during infancy, obesity and hormonal factors may synergistically enhance the burden of miR-21 expression. Recent progress in exosome-dependent cell signaling opens new avenues in understanding the interaction of exosomal miR-21 trafficking to melanocytes as well as MM-derived exosome signaling with cells of the tumor environment. Various environmental impacts on melanomagenesis converge in upregulated exosomal miR-21 signaling \[[@B151-cancers-12-02111]\], which finally modifies miR-21 homeostasis in cutaneous melanocytes ([Figure 4](#cancers-12-02111-f004){ref-type="fig"}). The missing correlation between miR-21 levels and NRAS and BRAF mutations in MM cells points to a mutation-independent pathway of miR-21-mediated signal transduction \[[@B39-cancers-12-02111]\].

Therefore, therapeutic agents that attenuate miR-21 expression such as metformin, beta-blockers, vitamin D, curcumin, EGCG and SFN may have beneficial effects in MM prevention and treatment. The anti-proliferative effects of miR-21-antagonizing agents, its catalytic knockdown of miR-21 by artificial ribonuclease, and miR-21 expression lowering agents may synergistically improve MM therapy \[[@B365-cancers-12-02111],[@B366-cancers-12-02111],[@B367-cancers-12-02111],[@B368-cancers-12-02111],[@B369-cancers-12-02111],[@B370-cancers-12-02111],[@B371-cancers-12-02111],[@B413-cancers-12-02111]\]. Delivery of exosomal anti-miR-21 may be a promising new option for MM treatment \[[@B367-cancers-12-02111],[@B368-cancers-12-02111],[@B369-cancers-12-02111],[@B370-cancers-12-02111]\]. The fact that VD/VDR signaling attenuates miR-21 expression \[[@B305-cancers-12-02111],[@B306-cancers-12-02111],[@B307-cancers-12-02111]\] suggests that VD deficient individuals should be given oral VD supplementation, and questions extensive use of sunscreens for MM prevention. Obviously, there should be an appropriate balance between UV-induced exosomal miR-21 expression and UV-stimulated vitamin D/VDR-mediated attenuation of miR-21 expression.

Future studies should characterize the epigenetic impact of Western lifestyle factors on aberrant exosomal miR-21 signaling in MM ([Figure 4](#cancers-12-02111-f004){ref-type="fig"}). A deeper understanding of the various cellular origins of miR-21-enriched exosomes on melanomagenesis and MM progression will hopefully open new avenues for the prevention and successful management of MM. Delivery of exosomal anti-miR-21 or interruption of MM exosome traffic, as well as attenuation of cellular miR-21 expression, may be promising future strategies for MM therapy.
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![Proposed model showing endogenous and extrinsic miR-21 expression in malignant melanoma (MM). RAS-MEK-ERK-AP-1 signaling as well as signal transducer and activator of transcription 3 (STAT3) signaling increases intracellular miR-21 expression. Yes-associated protein (YAP) and its homolog transcriptional coactivator with PDZ-binding motif (TAZ) increases FOS transcription activating AP-1 composed of FOS and JUN. Endogenous signals such as adrenaline via β-adrenergic receptors (B~1-2~AR) and endocrine hormones such as growth hormone (GH), obesity-induced leptin and inflammation-associated interleukin 6 (IL-6) upregulate STAT3, the enhancer of *MIR21*. Cellular miR-21 levels may be further increased by extrinsic exosome-derived miR-21 derived from various components of the MM environment. MiR-21 via suppression of B-cell translocation gene 2 (*BTG2*), Sprouty 1 (*SPRY1*), Sprouty 2 (*SPRY2*) and programmed cell death 4 (*PDCD4*) potentiates oncogenic RAS-MEK-ERK-AP-1 signal transduction in MM.](cancers-12-02111-g001){#cancers-12-02111-f001}

![Cell signaling pathways that undergo oncogenic dysregulation in melanoma (MM). Somatic gene mutations in MM, which include *KIT, NRAS, BRAF, MITF, PI3K, PTEN, AKT3*, and *NEDD9* (marked with asterisks), accelerate MM cell proliferation, survival, migration and invasion. In a similar manner, miR-21 promotes these oncogenic signaling pathways by downregulation of various tumor suppressors (*SPRY, BTG2, PTEN, PDCD4*) and inhibitors of mTORC1 and matrix metalloproteinases. MiR-21 inhibits apoptosis and cell cycle control via suppression of *BTG2, FBXO11*, and *FoxO1*. Via suppression of *SOX5*, miR-21 enhances the expression MITF. MiR-21 also attenuates MSH2 activity, thereby compromising DNA mismatch repair resulting in increased genetic instability. Cellular levels of miR-21 either increase by enhanced JAK2-STAT3 signaling or by exosomal transfer of miR-21 by cells of the MM microenvironment. Both somatic mutations in MM and epigenetic modifications of miR-21 have synergistical impacts on oncogenic signaling in MM.](cancers-12-02111-g002){#cancers-12-02111-f002}

![Illustration of exosome-driven melanomagenesis. Environmental and individual factors increase the total burden of miR-21-enriched exosomes. Melanoma (MM) cell levels of miR-21 increase steadily during melanomagenesis. Metastatic MM secretes high amounts of MM-derived miR-21- and PD-L1-enriched exosomes that compromise local and distant tumor defense mechanisms.](cancers-12-02111-g003){#cancers-12-02111-f003}

![Synoptic model depicting exosomal miR-21 traffic in the melanocyte and melanoma microenvironment. Cosmic and UV irradiation induce the release of keratinocyte-and fibroblast-derived miR-21-enriched exosomes, which may increase melanocyte miR-21 levels. Adipose tissue-derived exosomal miR-21 in obesity may further increase melanocyte miR-21 levels. Melanocyte miR-21 may be further enhanced by circulatory exosomes generated by a Western diet, milk consumption, smoking, inflammation, tumors and aging. Increased miR-21 levels in melanoma-associated macrophages and skin resident CD8+ memory T-cells further promote MM progression.](cancers-12-02111-g004){#cancers-12-02111-f004}

cancers-12-02111-t001_Table 1

###### 

MiR-21 expression in melanoma (MM) and related pathological effects.

  Associations of miR-21 with Melanoma Pathology                                                                                          References
  --------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  MiR-21 expression increases from benign nevi to MM and metastatic MM                                                                    \[[@B31-cancers-12-02111],[@B33-cancers-12-02111]\]
  MiR-21 expression correlates with mitotic activity in MM                                                                                \[[@B34-cancers-12-02111]\]
  MiR-21 levels correlate with MM cellularity                                                                                             \[[@B36-cancers-12-02111]\]
  MiR-21 promotes proliferation, migration, and inhibits apoptosis of MM cells                                                            \[[@B31-cancers-12-02111],[@B32-cancers-12-02111]\]
  MiR-21 expression correlates with Breslow thickness and advanced clinical stage                                                         \[[@B31-cancers-12-02111],[@B33-cancers-12-02111]\]
  MiR-21 expression correlates with positive sentinel lymph node biopsy                                                                   \[[@B34-cancers-12-02111]\]
  MiR-21 promotes MM invasion and metastasis                                                                                              \[[@B37-cancers-12-02111]\]
  MiR-21 expression correlates with shorter 5-year disease-free or overall survival                                                       \[[@B33-cancers-12-02111]\]
  MiR-21 inhibits PD-L1 expression of MM-associated macrophages                                                                           \[[@B38-cancers-12-02111]\]
  Antisense-mediated miR-21 inhibition suppresses growth, increases apoptosis and enhances chemo- or radiosensitivity of human MM cells   \[[@B33-cancers-12-02111]\]

PD-L1: programmed death ligand 1.

cancers-12-02111-t002_Table 2

###### 

MiR-21 target genes and their involvement in melanoma.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target Genes   Proteins                                                     Functions                                                                           References
  -------------- ------------------------------------------------------------ ----------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  *TIPE2*        Tumor necrosis factor-α-induced protein 8 (TNFAIP8)-like 2   Inhibition of RAS                                                                   \[[@B43-cancers-12-02111],[@B44-cancers-12-02111],[@B45-cancers-12-02111]\]

  *SPRY1*        Sprouty RTK signaling antagonist 1                           Inhibition of RAS and RAF                                                           \[[@B40-cancers-12-02111],[@B42-cancers-12-02111]\]

  *SPRY2*        Sprouty RTK signaling antagonist 2                           Inhibition of RAS and RAF                                                           \[[@B42-cancers-12-02111],[@B49-cancers-12-02111]\]

  *PTEN*         Phosphatase and tensin homolog                               Inhibition of PI3K and downstream\                                                  \[[@B40-cancers-12-02111],[@B49-cancers-12-02111]\]
                                                                              AKT-mTORC1 signaling                                                                

  *PDCD4*        Programmed cell death 4                                      Inhibition of translation initiation                                                \[[@B40-cancers-12-02111],[@B49-cancers-12-02111]\]

  *FBXO11*       F-box only protein 11                                        Tumor suppression promoting apoptosis, exhibiting decreased expression in higher\   \[[@B50-cancers-12-02111]\]
                                                                              Clark level MM                                                                      

  *SOX5*         SRY-box 5                                                    Suppression of MITF                                                                 \[[@B51-cancers-12-02111],[@B52-cancers-12-02111]\]

  *CDKN2C*       Cyclin-dependent kinase inhibitor 2C                         Inhibition of G~1~/S transition, proliferation                                      \[[@B32-cancers-12-02111],[@B49-cancers-12-02111]\]

  *MSH2*         DNA mismatch repair protein 2                                DNA repair, prevention of microsatellite\                                           \[[@B49-cancers-12-02111],[@B53-cancers-12-02111]\]
                                                                              instability                                                                         

  *CYP27B1*      25-hydroxyvitamin D~3~-1-α-hydroxylase                       Conversion of 25(OH) vitamin D to active\                                           \[[@B54-cancers-12-02111]\]
                                                                              1,25(OH)~2~ vitamin D~3~                                                            

  *RECK*         Reversion-inducing cysteine-rich protein with Kazal motifs   Extracellular matrix integrity and regulation of angiogenesis                       \[[@B49-cancers-12-02111],[@B55-cancers-12-02111]\]

  *TIMP1*        Tissue inhibitor of metalloproteinase 1                      Inhibition of MMP1-mediated matrix degradation                                      \[[@B49-cancers-12-02111],[@B56-cancers-12-02111]\]

  *TIMP3*        Tissue inhibitor of metalloproteinase 3                      Inhibition of MMP3-mediated matrix degradation                                      \[[@B49-cancers-12-02111],[@B57-cancers-12-02111]\]

  *CDH1*         E-cadherin                                                   Cell-cell adhesion                                                                  \[[@B58-cancers-12-02111]\]

  *IL12A*        p35 subunit of interleukin 12                                Anti-tumor activities via NK- and cytotoxic\                                        \[[@B59-cancers-12-02111]\]
                                                                              T cell activation                                                                   

  *AKT1S1*       AKT1 substrate 1, proline-rich                               Negative regulator of mTORC1                                                        \[[@B60-cancers-12-02111]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RTK: receptor tyrosine kinase; PI3K: phosphytidylinositol-3 kinase; mTORC1: mechanistic target of rapamaycin complex 1; MITF: microphthalmia-associated transcription factor; MMP: matrix metallo- proteinase; NK cell: natural killer T cell.

cancers-12-02111-t003_Table 3

###### 

Regulators of miR-21 expression.

  Regulatory Agent   Transcriptional Regulator                            MiR-21 Expression   References
  ------------------ ---------------------------------------------------- ------------------- -----------------------------------------------------------------------------------------------------------------------------
  AP1                Activator protein 1 (Fos, Jun)                       Upregulation        \[[@B25-cancers-12-02111],[@B92-cancers-12-02111]\]
  STAT3              Signal transducer and activator of transcription 3   Upregulation        \[[@B25-cancers-12-02111],[@B57-cancers-12-02111],[@B69-cancers-12-02111],[@B70-cancers-12-02111],[@B71-cancers-12-02111]\]
  p65                Nuclear factor kappa-B, subunit 3                    Upregulation        \[[@B25-cancers-12-02111]\]
  AR                 Androgen receptor                                    Upregulation        \[[@B25-cancers-12-02111],[@B93-cancers-12-02111]\]
  PU.1               ETS-domain transcription factor PU.1                 Upregulation        \[[@B25-cancers-12-02111]\]
  C/EBPα             CCATT/enhancer binding protein α                     Upregulation        \[[@B25-cancers-12-02111]\]
  TGFβ1              Transforming growth factor β1                        Upregulation        \[[@B25-cancers-12-02111]\]
  NFIB               Nuclear factor IB                                    Downregulation      \[[@B25-cancers-12-02111]\]
  VDR                Vitamin D receptor                                   Downregulation      \[[@B94-cancers-12-02111],[@B95-cancers-12-02111]\]
  XIST               X inactivation-specific transcript (lncRNA)          Downregulation      \[[@B79-cancers-12-02111]\]
  MEG3               Maternally expressed gene 3 (lncRNA)                 Downregulation      \[[@B58-cancers-12-02111]\]
  GAS5               Growth arrest specific transcript 5 (lncRNA)         Downregulation      \[[@B87-cancers-12-02111],[@B88-cancers-12-02111],[@B89-cancers-12-02111]\]

cancers-12-02111-t004_Table 4

###### 

Lifestyle factors upregulating miR-21 expression.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lifestyle Factor                Biological Responses                                                     References
  ------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------
  Ultraviolet radiation           Keratinocyte-derived release of miR-21-enriched\                         \[[@B163-cancers-12-02111],[@B164-cancers-12-02111],[@B165-cancers-12-02111],[@B166-cancers-12-02111],[@B167-cancers-12-02111]\]
                                  exosomes; increased miR-21 expression of melanocytes                     

  Cosmic irradiation              Increase of exosomal miR-21                                              \[[@B177-cancers-12-02111],[@B178-cancers-12-02111],[@B179-cancers-12-02111],[@B180-cancers-12-02111],[@B181-cancers-12-02111]\]

  Electromagnetic radiation       Increased expression of miR-21                                           \[[@B183-cancers-12-02111]\]

  Obese adipose tissue            Adipocyte secretome with increased release of miR-21-enriched exosomes   \[[@B232-cancers-12-02111],[@B233-cancers-12-02111],[@B234-cancers-12-02111],[@B235-cancers-12-02111],[@B236-cancers-12-02111]\]

  High-fat diet-induced obesity   Increase of circulatory and adipocyte miR-21                             \[[@B230-cancers-12-02111],[@B231-cancers-12-02111]\]

  High glucose intake             Increase of circulatory miR-21                                           \[[@B60-cancers-12-02111]\]

  High fructose intake            Increase of circulatory miR-21                                           \[[@B256-cancers-12-02111]\]

  Alcohol consumption             Increase of circulatory miR-21                                           \[[@B276-cancers-12-02111],[@B277-cancers-12-02111]\]

  Milk consumption                Increase of circulatory exosomal miR-21                                  \[[@B210-cancers-12-02111],[@B211-cancers-12-02111],[@B212-cancers-12-02111],[@B213-cancers-12-02111]\]

  Vitamin D deficiency            Increased expression of miR-21                                           \[[@B95-cancers-12-02111]\]

  Smoking                         Increased expression of exosomal miR-21\                                 \[[@B287-cancers-12-02111],[@B288-cancers-12-02111],[@B289-cancers-12-02111]\]
                                  in airway epithelial cells                                               

  Air pollution (Diesel)          Increased expression of exosomal miR-21\                                 \[[@B290-cancers-12-02111]\]
                                  in airway epithelial cells                                               

  Sedentary lifestyle             Increase of circulatory miR-21                                           \[[@B334-cancers-12-02111],[@B335-cancers-12-02111]\]

  Aging                           Increase of circulatory miR-21                                           \[[@B324-cancers-12-02111],[@B325-cancers-12-02111]\]

  Chronic inflammation            Increase of circulatory miR-21                                           \[[@B331-cancers-12-02111],[@B332-cancers-12-02111],[@B333-cancers-12-02111]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cancers-12-02111-t005_Table 5

###### 

Therapeutic interventions attenuating miR-21 expression.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Therapeutic Factors                         Potential Benefits for Melanoma Prevention and Therapy        References
  ------------------------------------------- ------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anti-miR-21                                 Direct suppression of miR-21 signaling in melanocytes,\       \[[@B33-cancers-12-02111],[@B366-cancers-12-02111],[@B367-cancers-12-02111],[@B368-cancers-12-02111],[@B369-cancers-12-02111],[@B370-cancers-12-02111],[@B371-cancers-12-02111]\]
                                              activation of skin-resident CD8+ memory T-cells;\             
                                              reduction of miR-21 in tumor-associated macrophages\          
                                              associated with improved cytotoxic T-cell responses           

  BRAF inhibition                             Attenuation of miR-21 expression                              \[[@B336-cancers-12-02111]\]

  Sunscreen                                   Reduction of keratinocyte-derived exosomal miR-21             \[[@B163-cancers-12-02111],[@B164-cancers-12-02111],[@B165-cancers-12-02111],[@B166-cancers-12-02111],[@B167-cancers-12-02111]\]

  Restriction of electro-magnetic radiation   Limitation of smart phone radiation on miR-21 expression      \[[@B189-cancers-12-02111],[@B190-cancers-12-02111]\]

  Control of birth weight and body weight     Balanced expression of miR-21 during fetal and\               \[[@B203-cancers-12-02111],[@B204-cancers-12-02111]\]
                                              postnatal life                                                

  Reduction of glycemic load and fat intake   Reduction of circulating and adipocyte-derived miR-21         \[[@B60-cancers-12-02111],[@B230-cancers-12-02111],[@B231-cancers-12-02111],[@B256-cancers-12-02111]\]

  Cessation of smoking                        Reduction of airway epithelial cell-derived exosomal miR-21   \[[@B287-cancers-12-02111],[@B288-cancers-12-02111],[@B289-cancers-12-02111]\]

  Restriction of alcohol intake               Reduction of miR-21 expression                                \[[@B276-cancers-12-02111],[@B277-cancers-12-02111]\]

  Metformin                                   Reduction of STAT3 activation and miR-21 expression           \[[@B349-cancers-12-02111],[@B350-cancers-12-02111],[@B352-cancers-12-02111],[@B353-cancers-12-02111]\]

  Beta-blocker                                Suppression of STAT3 activation and miR-21 expression         \[[@B364-cancers-12-02111]\]

  Curcumin                                    Suppression of STAT3 activation and inactivation of AP-1\     \[[@B380-cancers-12-02111],[@B381-cancers-12-02111],[@B382-cancers-12-02111],[@B383-cancers-12-02111]\]
                                              resulting in reduced expression of miR-21                     

  EGCG                                        Reduction of miR-21 expression                                \[[@B397-cancers-12-02111],[@B398-cancers-12-02111]\]

  Sulforaphane                                Reduction of miR-21 expression                                \[[@B388-cancers-12-02111],[@B389-cancers-12-02111]\]

  Vitamin D                                   Reduction of miR-21 expression                                \[[@B54-cancers-12-02111],[@B95-cancers-12-02111],[@B307-cancers-12-02111]\]

  Exercise                                    Reduction of miR-21 expression                                \[[@B334-cancers-12-02111],[@B335-cancers-12-02111]\]

  HIFU                                        Reduction of miR-21 in metastatic melanoma tissue             \[[@B376-cancers-12-02111]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
